Pharmacological treatment of diabetes in older people

Diabetes, Obesity and Metabolism

Volumn 16, Issue 12, 2014, Pages 1192-1203

  Valencia, W M ^a,b   Florez, H ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antidiabetic drug; Diabetes mellitus; Medicines management; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT;

AGE; AGED; AGING; COMORBIDITY; DAILY LIFE ACTIVITY; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE COURSE; DRUG INTERACTION; HEALTH CARE DELIVERY; HEALTH LITERACY; HUMAN; MEDICATION COMPLIANCE; PATIENT EDUCATION; POLYPHARMACY; PSYCHOLOGY; QUALITY OF LIFE; RISK FACTOR; SELF CARE; SOCIAL SUPPORT; VERY ELDERLY;

ACTIVITIES OF DAILY LIVING; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; COMORBIDITY; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE PROGRESSION; DRUG INTERACTIONS; HEALTH LITERACY; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYPOGLYCEMIC AGENTS; MEDICATION ADHERENCE; PATIENT EDUCATION AS TOPIC; POLYPHARMACY; QUALITY OF LIFE; RISK FACTORS; SELF CARE; SOCIAL SUPPORT;

EID: 84920273088     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12362     Document Type: Review

References (98)

1. International Diabetes Federation (Sinclair A, Dunning T, Colagiuri S: IDF Working Group Chair/Co-Chairs). IDF Global Guideline for Managing Older People with Type 2 Diabetes. Belgium, 2013. Available from URL: http://www.idf.org/guidelines/managing-older-people-type-2-diabetes. Accessed 8 March 2014.
2. Florez H, Oropesa L, Valencia W et al. Growing burden of diabetes in older adults: an analysis of the IDF Diabetes Atlas. World Diabetes Congress, Melbourne, 2013. Available from URL: www.idf.org/diabetesatlas. Accessed 14 November 2013.
3. Kirkman SM, Briscoe VJ, Clark N et al. Diabetes in older adults. Diabetes Care 2012; 35: 2650-2664.
4. Sinclair AJ, Paolisso G, Castro M, Bourdel-Marchasson I, Gadsby R, Rodriguez Manas L. European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary. Diabetes Metab 2011; 37(Suppl. 3): S27-S38.
5. Florez H, Marks J. Oral agents and insulin in care of older adults with diabetes. In: Munshi MN, Lipsitz LA, eds. Geriatric Diabetes. London: Informa Healthcare, 2007.
6. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011; 154: 554-559.
7. Munshi MN, Segal AR, Suhl E et al. Frequent hypoglycemia among elderly patients with poor glycemic control. Arch Intern Med 2011; 171: 362-364.
8. Lipska K, Wang Y, Ross J et al. National trends in hyperglycemia and hypoglycemia among medicare beneficiaries 1999-2011. Diabetes 2013; 62(Suppl. 1): A1-A98.
9. American Geriatrics Society (AGS). Guidelines abstracted from the AGS guidelines for improving the care of older adults with diabetes mellitus: 2013 Update. J Am Geriatr Soc 2013; 61: 2020-2026.
10. Blaum C, Cigolle CT, Boyd C et al. Clinical complexity in middle-aged and older adults with diabetes: the Health and Retirement Study. Med Care 2010; 48: 327-334.
11. Laiteerapong NIJ, Iveniuk J, John PM et al. Classification of older adults who have diabetes by comorbid conditions, United States, 2005-2006. Prev Chronic Dis 2012; 9: E100.
12. Pitale S, Kernan-Schroeder D, Emanuele N et al., VACSDM Study Group. Health-related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus. J Diabetes Complications 2005; 19: 207-211.
13. Munshi MN, Maguchi M, Segal AR. Treatment of type 2 diabetes in the elderly. Curr Diab Rep 2012; 12: 239-245.
14. Golay A. Metformin and body weight. Int J Obesity 2008; 32: 61-72.
15. Florez H, Luo J, Castillo-Florez S et al. Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Postgrad Med 2010; 122: 112-120.
16. American Association of Clinical Endocrinologist (AACE) 2013. Comprehensive diabetes management algorithm. Endocr Pract 2013; 19: 327-335.
17. American Diabetes Association. Standards of medical care in diabetes 2014. Diabetes Care 2014; 37(Suppl. 1): S15-S80.
18. Stang M, Wysowski D, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 1999; 22: 925-927.
19. Rydén L, Grant PJ, Anker SD et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2013; 34: 3035-3087.
20. Graham G, Punt J, Arora M et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011; 50: 81-98.
21. Solini A, Penno G, Bonora E et al. Age, renal dysfunction, cardiovascular disease, and anti-hyperglycemic treatment in type 2 diabetes mellitus: findings from the renal insufficiency and cardiovascular events Italian multicenter study. J Am Geriatr Soc 2013; 61: 1253-1261.
22. Bo S, Ciccone G, Rosato R et al. Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients. Diabetes Obes Metab 2012; 14: 23-29.
23. Currie CJ, Poole CD, Jenkins-Jones S, Gale EAM, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes. Diabetes Care 2012; 35: 299-304.
24. Lee CG, Boyko EJ, Barrett-Connor E et al. Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care 2011; 34: 2381-2386.
25. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304: 411-418.
26. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 2011; 342: d1309.
27. Bosetti C, Rosato V, Buniato D, Zambon A, La Vecchia C, Corrao G. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist 2013; 18: 148-156.
28. Bilik D, McEwen LN, Brown MB et al. Thiazolidinediones and fractures: evidence from translating research into action for diabetes. J Clin Endocrinol Metab 2010; 95: 4560-4565.
29. Solomon DH, Cadarette SM, Choudhry NK, Canning C, Levin R, Stürner T. A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab 2009; 94: 2792-2798.
30. Li H, Cui R, Cai H et al. The effect of thiazolidinediones on bone mineral density in Chinese older patients with type 2 diabetes. J Bone Miner Metab 2010; 28: 77-81.
31. Grey A, Bolland M, Fenwick S et al. The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. Eur J Endocrinol 2013; 170: 255-262.
32. Bolen S, Feldman L, Vassy J et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147: 386-399.
33. The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012; 60: 616-631.
34. Lapane KL, Yang S, Brown MJ, Jawahar R, Pagliasotti C, Rajpathak S. Sulfonylureas and risk of falls and fractures: a systematic review. Drugs Aging 2013; 30: 527-547.
35. Germino FW. Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review. Clin Ther 2011; 33: 1868-1882.
36. Schwarz SL, Gerich JE, Marcellari A, Jean-Louis L, Purkayastha D, Baron MA. Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes. Diabetes Obes Metab 2008; 10: 652-660.
37. Israel MK, Istvan E, Baron MA. Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes. Vasc Health Risk Manag 2008; 4: 1167-1178.
38. Juurinen L, Tiikkainen M, Saltevo J et al. Nateglinide combination therapy with basal insulin and metformin in patients with type 2 diabetes. Diabet Med 2009; 26: 409-415.
39. Rosenstock J, Hassman DR, Madder RD et al. Replaglinide versus nateglinide monotherapy. A randomized, multicenter study. Diabetes Care 2004; 27: 1265-1270.
40. Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf 2013; 12: 153-175.
41. Phillips P, Karrasch J, Scott R, Wilson D, Moses R. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care 2003; 26: 269-273.
42. Standl E, Schenll O. Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation. Diab Vasc Dis Res 2012; 9: 163-169.
43. Josse RG, Chiasson J-L, Ryan EA et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res Clin Pract 2003; 59: 37-42.
44. Mooradian A, Albert S, Witty S, Chehade J, Kim J, Bellrichard B. Dose-response profile of acarbose in older subjects with type 2 diabetes. Am J Med Sci 2000; 319: 334-337.
45. Sando KR, Taylor J. Bromocriptine: its place in type 2 diabetes Tx. J Fam Prac 2011; 60: E1-E5.
46. Gaziano JM, Cincotta AH, O'Connor CM et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes and overall safety and cardiovascular outcomes. Diabetes Care 2010; 33: 1503-1508.
47. Florez H, Scranton R, Farwell WR et al. Randomized clinical trial assessing the efficacy and safety of bromocriptine-QR when added to ongoing thiazolidinedione therapy in patients with type 2 diabetes mellitus. J Diabetes Metab 2011; 2: 142.
48. Ghosh A, Sengupta N, Sahana P, Giri D, Sengupta P, Das N. Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: a randomized open label phase IV clinical trial. Indian J Pharmacol 2014; 46: 24-28.
49. Li H, Wei C, Gao J et al. Mediation of dopamine D2 receptors activation in post-conditioning-attenuated cardiomyocyte apoptosis. Exp Cell Res 2014; 323: 118-130.
50. Kerr JL, Timpe EM, Petkewics KA. Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus. Ann Pharmacother 2010; 44: 1777-1785.
51. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin. Glucose and lipid effects. Arch Intern Med 2008; 168: 1975-1983.
52. Handelsman Y. Role of bile acid sequestrants in the treatment of type 2 diabetes. Diabetes Care 2011; 34(Suppl. 2): S244-S250.
53. Brunetti L, Campbell RK. Clinical efficacy of colesevelam in type 2 diabetes mellitus. J Pharm Pract 2011; 24: 417-425.
54. Marrs JC. Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes. Focus on combination therapy with colesevelam HCl. Drugs Aging 2012; 29: e1-e12.
55. Gallwitz B, Rosenstock J, Rauch T et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomized, double-blind, non-inferiority trial. Lancet 2012; 380: 475-483.
56. Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle H-J. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomized, double-blind, placebo control trial. Lancet 2013; 382: 1413-1423.
57. Karyekar CS, Ravichandran S, Allen E, Felming D, Frederich R. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥65 years) with inadequately controlled type 2 diabetes mellitus. Clin Interv Aging 2013; 8: 419-430.
58. Strain WD, Lukashevich V, Kothny W, Hoellinger MJ, Paldánius MP. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet 2013; 382: 409-416.
59. Schweizer A, Dejager S. Experience with vildagliptin in patients ≥75 years with type 2 diabetes and moderate or severe renal impairment. Diabetes Ther 2013; 4: 257-267.
60. Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab 2013; 15: 906-914.
61. Round E, Engel S, Golm G, Davies M, Kaufman K, Goldstein B. Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies. Drugs Aging 2014; 31: 203-214.
62. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010; 30: 463-484.
63. Van Genugten RE, van Raalte DH, Diamant M. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. Diabetes Obes Metab 2012; 14: 101-111.
64. Avogaro A, Dardano A, de Kreutzenberg SV, Del Prato S. Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes. Diabetes Obes Metab 2014; DOI: 10.1111/dom.12319[Epub ahead of print].
65. Chen LH, Leung PS. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus. Diabetes Obes Metab 2013; 15: 392-402.
66. Burki TK. FDA rejects novel diabetes drug over safety fears. Lancet 2012; 379: 507.
67. Cefalu WT, Leiter LA, Yoon K-H et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomized, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-950.
68. Bode B, Sentlöf K, Sullivan D, Fung A, Usisking K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 2013; 41: 72-84.
69. Yale J-F, Bakris G, Cariou B et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; 15: 463-473.
70. Thearle M, Brillantes AM. Unique characteristics of the geriatric diabetic population and the role for therapeutic strategies that enhance glucagon-like peptide-1 activity. Curr Opin Clin Nutr Metab Care 2005; 8: 9-16.
71. Dungan K, Buse JB. Glucagon-like peptide-1 based therapies for type 2 diabetes: a focus on exenatide. Clin Diabetes 2005; 23: 56-62.
72. Pawaskar M, Li O, Reynolds MW. Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting. Curr Med Res Opin 2012; 28: 991-997.
73. Buse JB, Nauck M, Forst T et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomized, open label study. Lancet 2013; 381: 117-124.
74. Minze MG, Kelin MS, Jernigan MJ, Wise SL, Frugé K. Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2013; 33: 627-638.
75. Bode BW, Brett J, Falahati A, Pratley RE. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies. Am J Geriatr Pharmacother 2011; 9: 423-433.
76. Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE. Efficacy and safety of the once-daily GLP-1 receptor antagonist lixisenatide in monotherapy. A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012; 35: 1225-1231.
77. Ahrén B, Dimas AL, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 2013; 36: 2543-2550.
78. Doggrell SA. Exenatide extended-release; clinical trials, patient preference, and economic considerations. Patient Prefer Adherence 2013; 7: 35-45.
79. VanDeKoppel S, Choe HM, Sweet BV. Managed care perspective on three new agents for type 2 diabetes. J Manag Care Pharm 2008; 14: 363-380.
80. Neumiller JJ, Setter S. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother 2009; 7: 324-342.
81. Mannucci E, Cremasco F, Romoli E, Rossi A. The use of insulin in elderly patients with type 2 diabetes mellitus. Expert Opin Pharmacother 2011; 12: 2865-2881.
82. Rossetti P, Ampudia-Blasco FJ, Ascaso JF. Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice. Diabetes Obes Metab 2014; 16: 695-706.
83. Gough SCL, Harris S, Woo V, Davies M. Insulin degludec: overview of a novel ultra long-acting basal insulin. Diabetes Obes Metab 2013; 15: 301-309.
84. European Medicines Agency website on insulin degludec. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002498/human_med_001609.jsp&mid=WC0b01ac058001d124. Accessed 17 July 2014.
85. A trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events (DEVOTE). Available from URL: http://clinicaltrials.gov/show/NCT01959529. Accessed 17 July 2014.
86. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013; 36: 1033-1046.
87. Pelletier C, Dai S, Roberts C, Bienek A, Onysko J, Pelletier L. Report summary. Diabetes in Canada: facts and figures from a public health perspective. Chronic Dis Inj Can 2012; 33: 53-54.
88. Tanaka T, Gjonça E, Gulliford MC. Income, wealth and risk of diabetes among older adults: cohort study using the English longitudinal study of ageing. Eur J Public Health 2012; 22: 310-317.
89. Bustacchini S, Corsonello A, Onder G et al. Pharmacoeconomics and aging. Drugs Aging 2009; 26(Suppl. 1): 75-87.
90. Hampp C, Borders-Hemphill V, Money DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003-2012. Diabetes Care 2014; 37: 1367-1374.
91. Asche CV, Hippler SE, Eurich DT. Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus. Pharmacoeconomics 2014; 32: 15-27.
92. Scheen AJ. Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes. Eur J Intern Med 2012; 23: 126-131.
93. Zhang Y, McCoy RZ, Mason JE, Smith SA, Shah NA, Denton BT. Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care 2014; 37: 1338-1345.
94. Beaudet A, Palmer JL, Timlin L et al. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. J Med Econ 2011; 14: 357-366.
95. Samyshkin Y, Guillermin AL, Best JH, Brunell SC, Lloyd A. Long-term cost-utility of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes in the US. J Med Econ 2012; 15(Suppl. 2): 6-13.
96. Fonseca T, Clegg J, Caputo G, Norrbacka K, Dilla T, Alvarez M. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain. J Med Econ 2013; 16: 926-938.
97. Fonseca VA. New developments in diabetes management: medications of the 21st century. Clin Ther 2014; 36: 477-484.
98. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association of the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.